Acute inflammatory and anabolic systemic responses to peak and constant-work-rate exercise bout in hospitalized patients with COPD by Spruit, Martijn A et al.
© 2007 Dove Medical Press Limited.   All rights reserved
International Journal of COPD 2007:2(4) 575–583 575
ORIGINAL RESEARCH
Acute inﬂ  ammatory and anabolic systemic 
responses to peak and constant-work-rate 






1Respiratory Rehabilitation and 
Respiratory Division, University 
Hospital Gasthuisberg, Leuven, 
Belgium; 2Department of 
Rehabilitation Sciences, Faculty 
of Kinesiology and Rehabilitation 
Sciences, Katholieke Universiteit 
Leuven, Leuven, Belgium; 3Laboratory 
of Experimental Immunology, Faculty 
of Medicine, Katholieke Universiteit 
Leuven, Leuven, Belgium
Correspondence: Marc Decramer
Respiratory Rehabilitation, University 
Hospital Gasthuisberg, Herestraat 49, 
B-3000, Leuven, Belgium
Tel/Fax +32 16 34 71 08 / 26
Email marc.decramer@uz.kuleuven.ac.be
Study objectives: To explore the acute systemic inﬂ  ammatory and anabolic effects of cycling 
in hospital admitted patients with chronic obstructive pulmonary disease (COPD) and in patients 
with clinically stable disease.
Design: Cross-sectional comparative study.
Setting: University Hospital Gasthuisberg, a tertiary care setting.
Patients: 16 patients with clinically stable COPD (no acute exacerbation in the past 12 weeks; 
median age: 73 years (IQR: 60 to 75); median forced expiratory volume in the ﬁ  rst second 
(FEV1): 45% predicted (IQR: 33 to 58)) and 14 patients who were admitted to a hospital due to 
an acute exacerbation of COPD (median age: 65 years (IQR: 59 to 74); median FEV1 on day 8 
of hospital stay: 41% predicted (IQR: 33 to 54)).
Interventions: None.
Measurements and results: Circulating levels of C reactive protein, interleukin 6, interleukin 
8 and insulin-like growth factor I were determined before, at the end and 2 and 30 minutes after a 
symptom-limited peak cycling test and before, at the end and 2 and 30 minutes after a symptom-
limited constant-work-rate cycling test at 70% of the peak load. Non-signiﬁ  cant changes in the 
circulating markers of inﬂ  ammation and anabolism were found during or up to 30 minutes after 
ceasing the peak or constant-work-rate cycling exercise tests. The systemic responses of the 
hospitalized patients with COPD did not differ from those with clinically stable disease.
Conclusions: High-intensity cycling exercises did not increase the circulating levels of inﬂ  am-
matory markers in patients with chronic obstructive pulmonary disease, irrespective of their 
clinical stability.
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Introduction
Patients with chronic obstructive pulmonary disease (COPD) have shown to have a 
systemic low-grade inﬂ  ammation in stable condition (Gan et al 2004), which transiently 
increases during acute exacerbations of COPD (Wedzicha et al 2000; Creutzberg et al 
2000; Dentener et al 2001; Spruit et al 2003). Low-grade systemic inﬂ  ammation may 
also be further aggravated during or following high-intensity exercise bouts. In fact, 
increased systemic inﬂ  ammation has been observed in patients with clinically stable 
COPD following 11 minutes of cycling at only ∼40% of peak external work rate as 
compared to baseline levels (Rabinovich et al 2003). The acute systemic effects of a 
single exercise bout may be more apparent in hospitalized patients with COPD, but 
has never been studied. Nevertheless, an increased systemic inﬂ  ammation following 
intensive exercises may also be expected in these patients and may result in addi-
tional increased plasma levels of ﬁ  brinogen (Wedzicha et al 2000), energy disbalance 
(Creutzberg et al 2000) and skeletal muscle weakness (Spruit et al 2003). Moreover, International Journal of COPD 2007:2(4) 576
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it may neutralize the beneﬁ  cial effects that exercise training 
may have in these patients (Man et al 2004). Finally, exercise-
induced cytokines may directly inhibit the activity of one of 
the major growth promoting factors (eg, insulin-like growth 
factor I (IGF-I)) (Fernandez-Celemin et al 2002). Sequen-
tially, this may reduce its circulating levels, as previously 
found in healthy adolescent boys (Nemet et al 2002) and 
in patients with cystic ﬁ  brosis (Tirakitsoontorn et al 2001). 
To date, the acute effects of cycling at a high intensity on 
circulating levels of IGF-I are unknown in patients with clini-
cally stable COPD or during an acute exacerbation.
Given the possible role of increased systemic inﬂ  amma-
tion and reduced systemic markers of the somatotrophic axis 
in the development and/or maintenance of skeletal muscle 
weakness in patients with COPD (Eid et al 2001; Debigare 
et al 2001, 2003; Spruit et al 2003), the present study was 
undertaken to further explore the acute systemic effects of 
cycling in hospital admitted patients with COPD and in those 
with stable disease. The authors hypothesized that COPD 
patients who are admitted to the hospital due to an acute 
exacerbation would have a higher inﬂ  ammatory response to 




Thirty patients with moderate-to-severe COPD (forced 
expiratory volume in 1 second (FEV1) /forced vital capacity 
(FVC)  70%) gave informed consent to participate in the 
present study, which was approved by the Medical Ethical 
Committee of the University Hospitals Leuven. Fourteen 
patients (10 men) were hospitalized while the remaining 
16 patients (13 men) did not have an acute COPD exacerba-
tion during at least 12 weeks preceding the tests.
Patients with COPD attended the emergency room due to 
a sustained worsening of the their condition, from the stable 
state and beyond normal day-to-day variations, that was 
acute in onset and required a change in regular medication 
(Rodriguez-Roisin 2000). The decision to admit patients to the 
hospital was made by the attending chest physician who was 
not familiar with the present study protocol. In 2 patients the 
presence of purulent sputum was documented in the patients’ 
ﬁ  le. In addition, 2 patients were classiﬁ  ed as having a type 
1 exacerbation, 3 patients had a type 2 exacerbation, while 
9 others had a type 3 exacerbation (Anthonisen et al 1987). 
Median circulating levels of C-reactive protein was 62.2 mg/l 
at the emergency room. Hospital admitted patients received 
32-milligram · day–1 oral methylprednisolone for 1 week, 
followed by 24-milligram · day–1 for a period of 4 days and 
a subsequent decrease of 4-milligram · week–1. No physical 
exercises were given during the hospital stay.
The acute systemic effects of exercise can be inﬂ  uenced 
by the intensity and type of the exercise bout (Schwarz et al 
1996; Ostrowski et al 2000). Therefore, the patients were 
asked to perform two different exercise tests on two separate 
days: a symptom-limited peak exercise test (at day 8 of 
hospitalization) and a symptom-limited constant-work-rate 
exercise test at ~70% of the peak external work rate (2–3 
days later). In addition, pulmonary function, quadriceps peak 
torque and the distance walked in 6 minutes were assessed as 
described previously (Gosselink et al 1996). All procedures 
were in accordance with the recommendations found in the 
World Medical Association declaration of Helsinki (Anon 
1997).
Symptom-limited peak exercise test
Peak exercise capacity was assessed by a symptom-limited 
peak exercise test on an electronically braked cycle-ergometer 
(Ergoline D-72475, Bitz, Germany). After a 2-minute rest-
ing period and 3 minutes of unloaded cycling, participants 
started at 20 watts and cycled until symptom limitation at an 
incremental workload (+10 watts/minute). Oxygen uptake 
(Vmax 29C Viasys Meda N.V., Edegem, Belgium), heart rate 
(Mac VS/ST, Marquette Electronics Inc.) and transcutaneous 
oxygen saturation (Datex-Ohmeda 3900) were measured 
during the test. At the end of the test Borg symptom scores 
for dyspnoea and fatigue were obtained from all participants 
(Borg 1998). Peak external work rate and peak oxygen 
uptake were normalized for height, age and gender (Jones 
et al 1985).
Symptom-limited constant-work-rate test
Endurance exercise capacity was assessed by a symptom-
limited constant-work-rate test, which is a reliable and 
valid method to assess exercise endurance in patients with 
COPD (van’t Hul et al 2003). This test was performed 
on the aforementioned cycle-ergometer. After a 2-min-
ute resting period and 3 minutes of unloaded cycling, 
participants started at ∼70% of their peak external work 
rate until symptom limitation. At the end of the test Borg 
symptom scores for dyspnea and fatigue were obtained 
from all participants.
Blood analyses
Venous blood samples were drawn before the start of both 
tests, directly at the end of the tests, and 2 and 30 minutes International Journal of COPD 2007:2(4) 577
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afterwards. They were directly centrifuged and stored at –80 
degrees Celsius. Circulating levels of interleukin 6 (IL-6) 
and interleukin 8 (CXCL8) were determined using Human 
Inﬂ  ammation Cytometric Bead Array (Becton Dickinson 
Biosciences, San Diego, CA, n = 23) (Cook et al 2001). 
C-reactive protein (CRP) was determined using an immu-
noturbidimetric assay (Roche Diagnostics Corporation, 
Indianapolis, USA, n = 30). IGF-I was determined using a 
radio-immuno assay (n = 30) (van den Berghe et al 2000).
Statistical analyses
Results are presented as median (interquartile range, IQR). 
A Mann-Whitney U test was used to determine possible dif-
ferences between physiological characteristics of hospitalized 
and clinically stable patients with COPD. Moreover, possible 
changes in systemic levels of IL-6, CXCL8, CRP, and IGF-I 
following exercise were analyzed by using a general linear 
models procedure repeated measures analysis of variance, 
incorporating baseline values as covariates. Spearman rank 
correlations (r) were used to determine relationships. A priori, 




On average, patients had moderate-to-severe COPD, 
normal body mass index, skeletal muscle weakness and 
reduced functional and peak exercise capacity (Table 1). 
As compared with the stable patients, hospitalized patients 
had signiﬁ  cantly lower values for the distance walked in 
6 minutes (Table 1). On average, both cycling exercise bouts 
were limited by reaching the maximal voluntary ventila-
tion. High Borg symptom scores for fatigue and dyspnoea 
conﬁ  rmed maximal effort (Tables 2 and 3). Oxygen uptake, 
heart rate and ventilation at the end of the symptom-limited 
constant-work-rate test were equal to the values obtained at 
the end of the symptom-limited peak exercise test in both 
groups (Table 3).
As compared to patients who cycled 10 minutes (n = 12), 
those with an endurance exercise time of 10 minutes (n = 18) 
were older (69 ± 7 versus 62 ± 10 years, p = 0.02), had a signiﬁ  -
cantly worse FEV1 (37 ± 12 versus 57 ± 14% of the reference 
values, p = 0.0005) and 6-min walking distance (50 ± 18% 
versus 80 ± 13% of the reference values, p = 0.0001), and 
tended to be weaker (quadriceps peak torque: 69 ± 29 versus 
80 ± 18% of the reference values; and maximal inspiratory 
mouth pressure: 68 ± 20 versus 82 ± 23% of the reference 
values, p = 0.08).
Acute anabolic response to exercise tests
At baseline, median circulating levels of IGF-I were not 
signiﬁ  cantly different between the patients admitted to the 
hospital [117 μg/l (87 to 149)] and those with stable disease 
[104 μg/l (84 to 123)]. Median circulating levels of IGF-I 
increased somewhat between the start of the tests and 2 
minutes after ceasing the exercise, directly followed by a 
reduction to baseline levels 30 minutes after exercise in both 
tests in both groups (Figure 1). These changes, however, 
did not reach the level of signiﬁ  cance over time or between 
groups.
Acute inﬂ  ammatory response
to exercise tests
Median baseline circulating levels of CRP and CXCL8 were 
not different between the patients admitted to the hospital [3.7 
mg/l (3.0–35.3) and 3.6 pg/ml (1.5–4.7), respectively] and 
those with stable disease [3.4 mg/l (3.0–7.2) and 2.7 pg/ml 
(2.1–3.5), respectively]. Neither median circulating levels 
of CRP (data not shown), nor circulating levels of CXCL8 
changed during or 30 minutes after either type of exercise 
bout in either group (Figure 2). Baseline systemic IL-6 could 
only be detected in 22% of the patients, and did not change 
signiﬁ  cantly during or after both exercise tests.
Discussion
The main objective of the present study was to compare the 
acute systemic anabolic and inﬂ  ammatory responses follow-
ing two types of exercise bouts in hospitalized patients with 
COPD with those of patients with clinically stable COPD. 
In both groups, IGF-I increased non-signiﬁ  cantly with ∼10% 
directly after exercise, but returned to baseline within 
30 minutes. No acute inﬂ  ammatory response was observed.
Acute systemic anabolic response
The somatotrophic axis is one of the major pathways of the 
endocrine system, which is involved in the protein synthesis 
and subsequent muscle hypertrophy. The present types of 
exercise did not result in statistically signiﬁ  cant increases in 
circulating levels of IGF-I (Figure 1). Nevertheless, transient 
changes in circulating levels of IGF-I during or following 
high-intensity exercise bouts have been reported (Schwarz 
et al 1996; Ehrnborg et al 2003). Although the source of this 
transient release of circulating IGF-I remains unknown, dif-
ferent potential origins can be present. Indeed, this may be a 
result of an increased release of growth hormone (Dall et al 
2000). Nevertheless, the acute exercise-induced increase in 
circulating levels of IGF-I appears to be independent of the International Journal of COPD 2007:2(4) 578
Spruit et al
circulating levels of growth hormone and of its response to 
exercise (Cappon et al 1994; Schwarz et al 1996; Hornum 
et al 1997). In fact, growth-hormone-releasing factor from 
the hypothalamus inﬂ  uences resting growth hormone secre-
tion by directly stimulating the anterior pituitary gland. In 
response to growth hormone stimulation, liver cells synthe-
size insulin-like growth factors (IGF) I, a process requiring 
between 8 and 30 hours.
Changes in circulating levels of IGF-I most probably do 
not reﬂ  ect possible changes in muscle IGF-I mRNA concen-
tration following exercise (Bamman et al 2001). Therefore, 
studies including muscle biopsies are necessary to understand 
to what degree acute transient changes in the circulating 
IGF-I levels are associated with the anabolic effects of one 
or more bouts of exercise in patients with COPD.
Inﬂ  ammatory response
In the present study, no signiﬁ  cant increases have been found 
in the circulating levels of CRP, IL-6 or CXCL8 during or 
after symptom-limited peak and constant-work-rate exercise 
bouts. This is in contrast with the results of Rabinovich and 
colleagues, who found increased systemic inﬂ  ammation after 
cycling for 11 minutes at ∼40% of the achieved peak external 
work rate (circulating levels of tumor necrosis factor-alpha: 
+6 pg/ml, without increases of circulating levels of IL-6 or 
soluble TNF receptors) (Rabinovich et al 2003). The reason 
for this discrepancy is unclear. The latter authors suggested 
that the increased circulating levels of inﬂ  ammatory mark-
ers are related to the exercise-induced muscle damage and 
the intensity and duration of the exercise (Rabinovich et al 
2003). Exercise bouts at ∼40% of achieved peak external 
Table 1 Characteristics
  Whole group  Hospitalized patients  Stable patients  p-value
Sex, M : F  23  : 7  10  : 4  13  : 3  –
Age,  years  69  (59–74)  65 (59–74)  73 (60–75)  0.43
Height,  cm  165  (160–171)  162 (157–169)  167 (163–172)  0.14
BMI, kg ⋅ m–2  25.6  (23.4–29.4)  25.2 (22.8–29.4)  25.8 (24.9–28.5) 0.92
FEV1,  l  1.09  (0.80–1.43)  1.06 (0.68–1.37)  1.18 (0.81–1.59) 0.42
FEV1, % reference  42  (33–55)  41  (33–54)  45  (33–58)  0.47
FEV1/FVC,  %  39  (35–46)  38 (36–45)  42 (34–47)  0.76
TL,CO, mmol kPa–1 min–1  3.3  (2.6–4.5)  3.0 (2.6–4.0)  3.7 (2.5–4.7)  0.42
TL,CO, % reference  42  (34–55)  41  (32–51)  50  (35–59)  0.30
6MWD,  m  398  (257–520)  251 (204–507)  439 (338–554)  0.04
6MWD, % reference  63  (43–78)  42  (37–72)  72  (56–85)  0.02
PImax, % reference  74  (58–83)  67  (54–79)  77  (63–88)  0.27
QPT, % reference  72  (61–89)  67  (43–81)  75  (66–93)  0.13
Values are expressed as median (interquartile range), except for gender distribution (absolute numbers). Male (M), female (F), meters (m), body mass index (BMI), body 
weight in kilograms per square height in metres (kg ⋅ m–2), forced vital capacity (FVC), litres (l), percent of the reference values (% reference), forced expiratory volume 
in the ﬁ  rst second (FEV1), percent (%), transfer factor for carbon monoxide of the lungs (TL,CO), distance walked in 6 minutes (6MWD), meters (m), maximal inspiratory 
pressure (PImax), and quadriceps peak torque (QPT). p-value: comparison between hospitalized and stable patients with COPD.
Table 2 Symptom-limited peak exercise test
  Whole group  Hospitalized patients  Stable patients  p-value
Peak load, watts  67  (47–100)  67  (37–88)  62  (52–113)  0.39
Peak load, % reference  56  (39–68)  50  (41–62)  64  (38–74)  0.31
Time,  s  325  (210–550)  345 (180–460)  309 (245–600)  0.38
Peak VO2, ml·min–1  855  (670–1201) 918 (669–1147) 802 (680–1258) 0.71
Peak VO2, % reference  51  (34–71)  47  (34–76)  52  (35–68)  0.90
HR,  bpm  129  (119–147)  132 (118–149)  128 (121–147)  0.90
HR, % HRmax calculated  86  (79–92)  88  (79–92)  86  (78–95)  0.76
VE, l·min–1  38.6  (31.0–54.7)  43.5 (23.5–54.7)  36.3 (31.8–52.3) 0.80
VE/MVV, %  96  (87–106)  105  (90–112)  94  (84–99)  0.10
Borg dyspnea, points  5  (5–7)  5  (5–9)  6  (4–7)  0.79
Borg fatigue, points  5  (4–6)  4  (3–5)  5  (4–7)  0.16
Lactate,  mmol  5.71  (4.25–7.87)  6.18 (4.27–7.67)  5.43 (3.89–8.06) 0.66
Values are expressed as median (interquartile range). Expressed as a percent of the reference values (% reference), seconds (s), oxygen uptake (VO2), millilitres per minute 
(ml ⋅ min–1), heart rate (HR), beats per minute (bpm), ventilation (VE), litres per minute (l ⋅ min–1), and maximum voluntary ventilation (MVV). p-value: comparison between 
hospitalized and stable patients with COPD.International Journal of COPD 2007:2(4) 579
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work rate are known to induce muscle damage in patients 
with COPD (Engelen et al 2001). Unfortunately, in the 
present study no biopsies of the vastus lateralis muscle were 
taken. Nevertheless, the present authors expect muscle dam-
age also to be present after exercise bouts at higher intensi-
ties (100% and 70% of the peak work load, respectively). 
Therefore, the duration of the exercise bouts may be the 
most important factor to induce signiﬁ  cant changes in the 
circulating inﬂ  ammatory status. Indeed, enormous transient 
increases in circulating levels of IL-6 and CXCL8 were 
found 15–30 minutes after prolonged, intense exercise in 
healthy athletes (Ostrowski et al 2001; Nieman et al 2003). 
In addition, higher gene expression of several cytokines, of 
which the increase in muscle CXCL8 (up to 23.3-fold of 
Table 3 Symptom-limited constant-work-rate exercise test
  Whole group  Hospitalized patients  Stable patients  p-value
Load,  watts  47  (27–67)  48 (27–62)  42 (36–72)  0.43
Load, % peak test  69  (63–73)  71  (63–73)  67  (62–73)  0.88
Time,  s  455  (260–880)  385 (250–980)  480 (270–805)  0.65
VO2, ml·min–1  867  (659–1202) 909 (681–1153) 845 (626–1258) 0.79
VO2, % peak test  99  (88–106)  99  (86–104)  97  (88–107)  0.92
HR,  bpm  133  (117–146)  139 (126–151)  131 (104–143)  0.23
HR, % peak test  100  (93–107)  102  (98–109)  98  (88–106)  0.21
VE, l·min–1  38.1  (30.6–55.7)  44.9 (25.3–55.7)  34.9 (32.4–53.7) 0.82
VE/MVV, %  95  (79–114)  113  (92–115)  90  (73–95)  0.02
Borg dyspnoea, points  5  (4–7)  4  (3–6)  7  (4–7)  0.07
Borg fatigue, points  5  (4–7)  5  (4–7)  5  (4–6)  0.83
Lactate,  mmol  5.66  (4.34–7.64)  6.73 (5.76–8.82)  4.86 (3.90–5.83) 0.03
Values are expressed as median (interquartile range). Expressed as a percent of the reference values (% reference), seconds (s), oxygen uptake (VO2), millilitres per minute 
(ml ⋅ min–1), heart rate (HR), beats per minute (bpm), ventilation (VE), litres per minute (l ⋅ min–1), and maximum voluntary ventilation (MVV). P-value: comparison between 









































































Figure 1 Median (interquartile range) circulating levels of insulin-like growth factor I (IGF-I, expressed in μg/l) at baseline, at the peak and 2 and 30 minutes following a 
symptom-limited peak exercise test in hospitalized patients with COPD (Panel A) and clinically stable patients with COPD (Panel B). Median (interquartile range) circulating 
levels of IGF-I at baseline, at the end and 2 and 30 minutes following a symptom-limited constant-work-rate endurance test in hospitalized patients with COPD (Panel C) and 
clinically stable patients with COPD (Panel D).International Journal of COPD 2007:2(4) 580
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baseline values) was the largest after running at ∼70% of 
the peak oxygen uptake for 3 hours (Nieman et al 2003). So, 
in the present study the exercise duration was probably too 
short to induce transient changes in the circulating levels of 
CRP, IL-6 or CXCL8 (median duration peak exercise test: 
5.30 min; median duration constant-work-rate exercise test: 
7.30 min). On the other hand, 5 minutes of exhaustive local 
exercise resulted in increased systemic and local oxidative 
stress in patients with COPD as compared with healthy age-
matched controls (Couillard et al 2002, 2003). This topic 
warrants further investigation.
Clinical implications
High-intensity exercise training appears to be the most 
efﬁ  cient treatment-modality to partially restore muscle 
function, exercise tolerance and health-related quality of 
life in patients with stable COPD (Casaburi et al 1991; 
Maltais et al 1996, 1997; Bernard et al 1999; Neder et al 
2000; Troosters et al 2000; Spruit et al 2002). The present 
study showed no acute systemic inﬂ  ammatory response 
to high-intensity cycling bouts which were of a relatively 
short duration in patients with COPD who recently have 
been admitted to the hospital. Therefore, it appears that the 
effects of interval-type of exercise training can be studied 
in patients with COPD who recently have been discharged 
from the hospital due to an acute exacerbation of COPD. In 
fact, Man and colleagues (2004) found a favorable effect of 
exercise training on health-related quality of life and func-
tional exercise capacity in patients with COPD directly after 
discharge from the hospital as compared to a control group. 
Although the latter study did not report on the intensity and 
duration of the various exercises, from the current results 
it can be concluded that on average it is probably safe to 
perform interval-type of exercises (Vogiatzis et al 2002) 
in patients that have recently experienced a severe acute 
exacerbation of COPD.
Older and physically weaker patients with a forced expira-
tory volume in the ﬁ  rst second of around or less than 40% of 
the predicted values, are not likely to be able to sustain high-
intensity endurance-type of exercises. Interval training, resis-
tance training and/or transcutaneous neuromuscular electrical 
stimulation should be considered in these patients (Simpson 
et al 1992; Coppoolse et al 1999; Bourjeily-Habr et al 2002; 

















































































Figure 2 Median (interquartile range) circulating levels of interleukin 8 (CXCL8, expressed in pg/ml) at baseline, at the peak and 2 and 30 minutes following a symptom-
limited peak exercise test in hospitalized patients with COPD (Panel A) and clinically stable patients with COPD (Panel B). Median (interquartile range) circulating levels 
of CXCL8 at baseline, at the end and 2 and 30 minutes following a symptom-limited constant-work-rate endurance test in hospitalized patients with COPD (Panel C) and 
clinically stable patients with COPD (Panel D).International Journal of COPD 2007:2(4) 581
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Limitations of the study
At ﬁ  rst sight, it is somewhat surprising that the hospitalized 
patients and the clinically stable patients had a similar peak 
exercise tolerance (Table 2) and a signiﬁ  cantly different func-
tional exercise capacity eg, the distance walked in 6 minutes 
(Table 1). Nonetheless, peak exercise capacity has shown 
be related to pulmonary function impairment (especially 
tranfer factor for carbon monoxide) (Gosselink et al 1996), 
which was similar between the two groups (Table 1). On 
the other hand, the distance walked in 6 minutes has shown 
to be more related to the quadriceps muscle weakness in 
patients with COPD (Gosselink et al 1996), which tended 
to be signiﬁ  cantly different between the two patient groups 
in the present study.
The severity of the exacerbation may be questioned because 
hospitalized patients had similar pulmonary function and body 
mass index as the clinically stable patients (Table 1). Nonethe-
less, the characteristics and skeletal muscle force of the hospi-
talized patients were not signiﬁ  cantly different from a previous 
unrelated study (Spruit et al 2003). In contrast, the present 
clinically stable patients appear to have worse physical charac-
teristics as seen previously (Spruit et al 2003). This is probably 
because the current patients were free of an acute exacerbation 
for at least three months, while previously this period was set 
at 1 year (Spruit et al 2003). Nevertheless, this indicates again 
that also patients with clinically stable COPD that attend the 
outpatient consultation of a tertiary care setting are particularly 
in need of pulmonary rehabilitation (Spruit et al 2004).
The present authors were interested in the acute systemic 
inﬂ  ammatory response following a symptom-limited peak 
exercise test and constant-work-rate exercise test in hospi-
talized patients who were about to be discharged from the 
hospital. In the present setting, patients are admitted for about 
10 days. Therefore, the symptom-limited peak exercise test 
had to be done at day 8. Moreover, the patients that Man and 
colleagues included in their rehabilitation study were also 
tested after a mean hospital stay of 8 days (Man et al 2004). 
Whether and to what extent exercise-induced increases will 
occur in systemic inﬂ  ammation earlier during the acute COPD 
exacerbation remains unknown. In addition, by only taking 
blood samples up to 30 minutes after ceasing the exercise 
tests, the present study may have missed a later inﬂ  ammatory 
response. In fact, important changes in inﬂ  ammatory gene 
transcription may result from exercise but would probably 
not have been detected within 30 minutes. Nonetheless, cir-
culating levels of CXCL8 increased signiﬁ  cantly following 
prolonged high-intensity exercise in healthy athletes, with a 
peak at 30 minutes (Ostrowski et al 2001).
Finally, the present study did not assess body composi-
tion, which recently has been shown to partially inﬂ  uence the 
exercise-induced systemic inﬂ  ammatory response in COPD 
(Van Helvoort et al 2006).
Conclusion
Patients with stable COPD have a reduced physical function 
(Gosselink et al 1996), which deteriorates during an acute 
exacerbation of COPD (Spruit et al 2003). Therefore, the 
latter patients have a clear indication to start exercise train-
ing following an acute COPD exacerbation. The present 
study has shown that hospital admitted patients have similar 
acute systemic responses to high-intensity exercise cycling 
as compared to the responses of patients with stable disease. 
Thus, high-intensity cycling exercises for 10 minutes or less 
seem feasible in patients directly after an acute exacerbation. 
The present study adds evidence that changes in several 
inﬂ  ammatory markers do not occur with exercise in COPD 
irrespective of their clinical stability.
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